Do analysts rate TRIB or RVP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Retractable Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media refer more to TRIB or RVP?

In the previous week, Trinity Biotech had 1 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Retractable Technologies. Trinity Biotech's average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Retractable Technologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TRIB or BEAT?

HeartBeam has a consensus target price of $4.00, indicating a potential upside of 854.65%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartBeam 1 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.56

Does the media refer more to TRIB or BEAT?

In the previous week, Trinity Biotech and Trinity Biotech both had 2 articles in the media. Trinity Biotech's average media sentiment score of 0.00 equaled HeartBeam'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartBeam 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer TRIB or LFWD?

Lifeward has a consensus price target of $10.00, indicating a potential upside of 65.84%. Given Lifeward's stronger consensus rating and higher possible upside, analysts clearly believe Lifeward is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lifeward 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is TRIB or LFWD more profitable?

Trinity Biotech has a net margin of -70.06% compared to Lifeward's net margin of -141.28%. Trinity Biotech's return on equity of 0.00% beat Lifeward's return on equity. Company Net Margins Return on Equity Return on Assets Trinity Biotech -70.06% N/A -32.13% Lifeward -141.28% -235.86% -81.72%

Does the media favor TRIB or LFWD?

In the previous week, Trinity Biotech and Trinity Biotech both had 2 articles in the media. Lifeward's average media sentiment score of 0.91 beat Trinity Biotech's score of 0.00 indicating that Lifeward is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lifeward 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TRIB or HSCS?

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 105.66%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to TRIB or HSCS?

In the previous week, Trinity Biotech had 1 more articles in the media than HeartSciences. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.26 beat Trinity Biotech's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trinity Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral HeartSciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer FEMY or TRIB?

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 2,280.95%. Given Femasys' stronger consensus rating and higher possible upside, research analysts clearly believe Femasys is more favorable than Trinity Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Femasys 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Trinity Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FEMY or TRIB more profitable?

Trinity Biotech has a net margin of -70.06% compared to Femasys' net margin of -534.36%. Trinity Biotech's return on equity of 0.00% beat Femasys' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% Trinity Biotech -70.06% N/A -32.13%

Trinity Biotech (TRIB) Competitors

$6.32 -0.11 (-1.71%)

Closing price 10/1/2026 03:47 PM Eastern

Extended Trading

$6.32 0.00 (-0.02%)

As of 07:00 AM Eastern

Compare

TRIB vs. RVP, BEAT, LFWD, HSCS, and FEMY

Should you buy Trinity Biotech stock or one of its competitors? Trinity Biotech's main competitors and comparable companies include Retractable Technologies (RVP), HeartBeam (BEAT), Lifeward (LFWD), HeartSciences (HSCS), and Femasys (FEMY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment & supplies" industry.

How does Trinity Biotech compare to Retractable Technologies?

Trinity Biotech (NASDAQ:TRIB) and Retractable Technologies (NYSE:RVP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Retractable Technologies has a net margin of -41.11% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat Retractable Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Trinity Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Retractable Technologies has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Retractable Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Retractable Technologies has lower revenue, but higher earnings than Trinity Biotech. Retractable Technologies is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.12	-$37.38M	-$44.26	N/A
Retractable Technologies	$33.90M	0.61	-$7.01M	-$0.12	N/A

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 59.5% of Retractable Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Trinity Biotech had 1 more articles in the media than Retractable Technologies. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for Retractable Technologies. Trinity Biotech's average media sentiment score of 0.00 equaled Retractable Technologies'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Retractable Technologies	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Retractable Technologies beats Trinity Biotech on 7 of the 13 factors compared between the two stocks.

How does Trinity Biotech compare to HeartBeam?

Trinity Biotech (NASDAQ:TRIB) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

HeartBeam has lower revenue, but higher earnings than Trinity Biotech. HeartBeam is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.12	-$37.38M	-$44.26	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 7.8% of HeartBeam shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 18.0% of HeartBeam shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Trinity Biotech and Trinity Biotech both had 2 articles in the media. Trinity Biotech's average media sentiment score of 0.00 equaled HeartBeam'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartBeam	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartBeam has a consensus target price of $4.00, indicating a potential upside of 854.65%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts clearly believe HeartBeam is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartBeam	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Trinity Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.76, indicating that its share price is 176% less volatile than the broader market.

HeartBeam has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
HeartBeam	N/A	-686.78%	-348.65%

Summary

HeartBeam beats Trinity Biotech on 8 of the 14 factors compared between the two stocks.

How does Trinity Biotech compare to Lifeward?

Trinity Biotech (NASDAQ:TRIB) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Trinity Biotech has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Lifeward has a consensus price target of $10.00, indicating a potential upside of 65.84%. Given Lifeward's stronger consensus rating and higher possible upside, analysts clearly believe Lifeward is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Trinity Biotech and Trinity Biotech both had 2 articles in the media. Lifeward's average media sentiment score of 0.91 beat Trinity Biotech's score of 0.00 indicating that Lifeward is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lifeward	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifeward has lower revenue, but higher earnings than Trinity Biotech. Lifeward is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.12	-$37.38M	-$44.26	N/A
Lifeward	$22.03M	0.77	-$19.91M	-$16.82	N/A

Trinity Biotech has a net margin of -70.06% compared to Lifeward's net margin of -141.28%. Trinity Biotech's return on equity of 0.00% beat Lifeward's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
Lifeward	-141.28%	-235.86%	-81.72%

Summary

Trinity Biotech beats Lifeward on 8 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to HeartSciences?

Trinity Biotech (NASDAQ:TRIB) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Trinity Biotech has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

In the previous week, Trinity Biotech had 1 more articles in the media than HeartSciences. MarketBeat recorded 2 mentions for Trinity Biotech and 1 mentions for HeartSciences. HeartSciences' average media sentiment score of 0.26 beat Trinity Biotech's score of 0.00 indicating that HeartSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trinity Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
HeartSciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

HeartSciences has a consensus target price of $8.00, indicating a potential upside of 105.66%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

HeartSciences has lower revenue, but higher earnings than Trinity Biotech. HeartSciences is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trinity Biotech	$43.78M	0.12	-$37.38M	-$44.26	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.22	N/A

HeartSciences has a net margin of 0.00% compared to Trinity Biotech's net margin of -70.06%. Trinity Biotech's return on equity of 0.00% beat HeartSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trinity Biotech	-70.06%	N/A	-32.13%
HeartSciences	N/A	-816.90%	-181.97%

79.0% of Trinity Biotech shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 4.9% of HeartSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

HeartSciences beats Trinity Biotech on 8 of the 15 factors compared between the two stocks.

How does Trinity Biotech compare to Femasys?

Femasys (NASDAQ:FEMY) and Trinity Biotech (NASDAQ:TRIB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Trinity Biotech has a net margin of -70.06% compared to Femasys' net margin of -534.36%. Trinity Biotech's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
Trinity Biotech	-70.06%	N/A	-32.13%

Femasys presently has a consensus target price of $50.00, indicating a potential upside of 2,280.95%. Given Femasys' stronger consensus rating and higher possible upside, research analysts clearly believe Femasys is more favorable than Trinity Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Trinity Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

65.3% of Femasys shares are held by institutional investors. Comparatively, 79.0% of Trinity Biotech shares are held by institutional investors. 7.8% of Femasys shares are held by company insiders. Comparatively, 8.2% of Trinity Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Femasys has a beta of -2.15, indicating that its stock price is 315% less volatile than the broader market. Comparatively, Trinity Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market.

Femasys has higher earnings, but lower revenue than Trinity Biotech. Femasys is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	7.68	-$18.63M	-$3.53	N/A
Trinity Biotech	$43.78M	0.12	-$37.38M	-$44.26	N/A

In the previous week, Trinity Biotech had 2 more articles in the media than Femasys. MarketBeat recorded 2 mentions for Trinity Biotech and 0 mentions for Femasys. Femasys' average media sentiment score of 0.00 equaled Trinity Biotech'saverage media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
Trinity Biotech	Neutral

Summary

Trinity Biotech beats Femasys on 9 of the 15 factors compared between the two stocks.

Get Trinity Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRIB vs. The Competition

Export

Metric	Trinity Biotech	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.23M	$5.49B	$7.23B	$13.08B
Dividend Yield	N/A	1.80%	2.53%	15.88%
P/E Ratio	-0.14	24.39	272.66	25.80
Price / Sales	0.12	68.20	607.38	90.99
Price / Cash	N/A	32.68	77.38	51.29
Price / Book	-0.01	5.61	11.09	6.26
Net Income	-$37.38M	$150.14M	$3.50B	$360.95M
7 Day Performance	-6.51%	-1.80%	-2.02%	-1.81%
1 Month Performance	-34.17%	-5.30%	-6.43%	-4.03%
1 Year Performance	-80.13%	2.85%	8.98%	2.18%

Trinity Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRIB Trinity Biotech	0.4796 of 5 stars	$6.32 -1.7%	N/A	-79.3%	$5.23M	$43.78M	N/A	287	Gap Down
RVP Retractable Technologies	N/A	$0.69 +0.9%	N/A	-17.8%	$20.75M	$33.90M	N/A	201
BEAT HeartBeam	1.9342 of 5 stars	$0.37 -1.3%	$4.00 +987.0%	-74.8%	$20.74M	N/A	N/A	1,700	News Coverage Analyst Forecast
LFWD Lifeward	2.6505 of 5 stars	$7.02 +1.4%	$10.00 +42.5%	-29.1%	$19.87M	$22.03M	N/A	81	News Coverage Gap Down
HSCS HeartSciences	2.6717 of 5 stars	$4.14 -6.6%	$8.00 +93.3%	+9.0%	$19.86M	N/A	N/A	14

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRIB) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trinity Biotech (TRIB) Competitors

TRIB vs. RVP, BEAT, LFWD, HSCS, and FEMY

How does Trinity Biotech compare to Retractable Technologies?

Summary

How does Trinity Biotech compare to HeartBeam?

Summary

How does Trinity Biotech compare to Lifeward?

Summary

How does Trinity Biotech compare to HeartSciences?

Summary

How does Trinity Biotech compare to Femasys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trinity Biotech (TRIB) Competitors

TRIB vs. RVP, BEAT, LFWD, HSCS, and FEMY

How does Trinity Biotech compare to Retractable Technologies?

Is TRIB or RVP more profitable?

Which has more volatility and risk, TRIB or RVP?

Do analysts rate TRIB or RVP?

Which has stronger valuation & earnings, TRIB or RVP?

Do institutionals and insiders have more ownership in TRIB or RVP?

Does the media refer more to TRIB or RVP?

Summary

How does Trinity Biotech compare to HeartBeam?

Which has higher earnings & valuation, TRIB or BEAT?

Do insiders & institutionals hold more shares of TRIB or BEAT?

Does the media refer more to TRIB or BEAT?

Do analysts rate TRIB or BEAT?

Which has more volatility & risk, TRIB or BEAT?

Is TRIB or BEAT more profitable?

Summary

How does Trinity Biotech compare to Lifeward?

Which has more risk & volatility, TRIB or LFWD?

Do analysts prefer TRIB or LFWD?

Do institutionals and insiders hold more shares of TRIB or LFWD?

Does the media favor TRIB or LFWD?

Which has higher valuation and earnings, TRIB or LFWD?

Is TRIB or LFWD more profitable?

Summary

How does Trinity Biotech compare to HeartSciences?

Which has more risk and volatility, TRIB or HSCS?

Does the media refer more to TRIB or HSCS?

Do analysts prefer TRIB or HSCS?

Which has preferable earnings & valuation, TRIB or HSCS?

Is TRIB or HSCS more profitable?

Do institutionals & insiders hold more shares of TRIB or HSCS?

Summary

How does Trinity Biotech compare to Femasys?

Is FEMY or TRIB more profitable?

Do analysts prefer FEMY or TRIB?

Do insiders and institutionals believe in FEMY or TRIB?

Which has more risk & volatility, FEMY or TRIB?

Which has preferable valuation and earnings, FEMY or TRIB?

Does the media prefer FEMY or TRIB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRIB vs. The Competition

Trinity Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools